Spark Restores Vision In Phase III; CEO Hopes To Lead Gene Therapy Field
This article was originally published in Scrip
Executive Summary
Spark Therapeutics is preparing to seek the first-ever US FDA approval for a gene therapy after several people who couldn't read a menu in a dimly lit restaurant or take a walk alone at dusk had their vision restored in a Phase III clinical trial testing SPK-RPE65.
You may also be interested in...
Spark Sets Sights On Bringing First Gene Therapy To Market In 2018
A BLA for a potential gene therapy to correct vision loss due to certain inherited retinal disease has been accepted by FDA with a Jan. 12 PDUFA date. The proposed trade name is Luxturna.
Spark Therapeutics Now Targets 2017 For US Approval Of First Retinal Gene Therapy
Two manufacturing control assays have taken longer to develop than previously thought, putting back completion of a BLA submission to early 2017 for US company Spark Therapeutics, while further progress has been made in the company’s early-stage hemophilia gene therapy program.
Finance Watch: Pfizer Adds $3.5bn To Cash Stockpile, Reduces Stake In Haleon
Public Company Edition: Pfizer’s stake in Haleon dropped from 32% to 22.6% with a massive sale of shares of the GSK consumer health spinout. Also, Galderma prices its Swiss IPO, Madrigal grosses $600m in a post-approval offering and bluebird secured up to $175m in debt.